Orri - Gresham House Ventures

Orri offers in-person and virtual eating disorder (ED) services.

Orri provides an important service in a growing area where NHS services contend with insufficient budgets to meet the rising demand. Its recovery-focused programmes fill the gap between primary and inpatient services, offering a step-down model to support the transition back to everyday life in recovery.

Orri is rated as an ‘outstanding’ treatment provider by the Care Quality Commission (CQC).

Our first investment of £4.5mn in September 2022, led by Maya Ward, was used to open a second site, as well as to accelerate growth in their online services, providing a step-down outpatient service and building out their team.

In 2024, we made two follow-on investments totalling £1.5mn.

Investment team

Maya Ward

Investment Director

Maya joined Gresham House in September 2019, and focuses on healthcare investments, including Orri, Metrion Biosciences and Panthera Biopartners.

Prior to Gresham House, she spent 4 years at Octopus Investments, investing in real estate-backed healthcare companies and entrepreneurs. Before this she worked at KPMG for 7 years in audit and corporate finance.

Maya holds a first-class degree in Modern History and is a Chartered Accountant (ICAEW).

Outside of work, Maya enjoys playing hockey (when not suffering from an injury!), travelling and watching martial arts films.

It’s a pleasure to be investing in the future of UK healthcare across a range of sub sectors and working with some of the country’s top scientists and clinicians to deliver world-class solutions.